Progen is still up substantially for the year, but this is seen as unjustified with the long and expensive Phase III process before us. Many analysts see a correction and re-rating to the $2 - $2.50 range until the end of 2008 (when interim results of the trial will likely be available).
Current prices represent excellent value to the seller. All signs point to her going lower.
